Calculator
Compound comparison
Compare research peptides side by side: class, half-life, route studied, research stage and regulatory status.
| BPC-157 | TB-500 | |
|---|---|---|
| Category | Tissue repair and recovery | Tissue repair and recovery |
| Class | Synthetic pentadecapeptide based on a fragment of human gastric juice protein BPC | Synthetic 7 amino acid fragment of the 43 amino acid protein thymosin beta-4 |
| Half-life | Not established | Not established |
| Route studied | Subcutaneous injection on the research market; tested orally and by injection in animal studies | Subcutaneous injection on the research market, as the short fragment; the full-length protein has been dosed by injection, topically and as eye drops in trials |
| Research stage | A large rodent literature on tendon, ligament, muscle, gut and nerve injury. One published human report, a case series of intra-articular knee injections. No controlled human trial found | Full-length thymosin beta-4 has cell, animal and some human trial data. The short TB-500 fragment sold as a research chemical has almost no published data of its own beyond recent rat studies alongside BPC-157 |
| Regulatory | Not an approved drug anywhere. Not registered with FDA Philippines. Nominated to the US FDA's compounding safety-risk list in 2023; the nomination was withdrawn in April 2026 | Not registered with FDA Philippines. Nominated to the US FDA's compounding safety-risk list in 2023 as thymosin beta-4, fragment; the nomination was withdrawn in April 2026. Thymosin beta-4 is on the WADA Prohibited List |